# Randomized Trial to Assess the Safety and Tolerability of Daily Intake of an Allulose Amino Acid-Based Hydration Beverage in Men and Women

**Authors:** Richard J. Bloomer, Jacquelyn Pence, Janine Hellenbrand, Allyson Davis, Samantha Davis, Michelle Stockton, Keith R. Martin

PMC · DOI: 10.3390/nu16111766 · Nutrients · 2024-06-05

## TL;DR

A hydration beverage with amino acids and vitamins was tested for safety and tolerability in 40 people over 4 weeks, showing no significant adverse effects.

## Contribution

The study provides empirical evidence on the safety of an allulose amino acid-based hydration beverage in a controlled trial.

## Key findings

- The product was well-tolerated at all dosing levels with no significant adverse changes compared to placebo.
- Mild gastrointestinal disturbances were observed but not physiologically significant.
- No major changes in hematological, metabolic, or thyroid parameters were noted.

## Abstract

Background: Maintaining adequate hydration is critical to optimal health, well-being, and performance. Those who are physically active in stressful environments, such as warm and/or humid scenarios, may be at particular risk for dehydration with ensuing loss of electrolytes, leading to sluggishness and impaired physical performance. Methods: We evaluated an electrolyte and amino acid product containing L-alanine and L-glutamine, as well as select vitamins [B3 (niacin), B5 (pantothenic acid), B6 (pyridoxine), B12 (cobalamin), and vitamin C (ascorbic acid)]. Subjects (n = 40; four groups, n = 10) were randomized to consume either a placebo packet or one, two, or three packets daily of the test product for 4 weeks with site visits at 0, 2, and 4 weeks. We tested safety and tolerability by analyzing hematological parameters (complete blood counts), metabolic parameters (hepatic, renal, acid–base balance), urinalysis end products, thyroid status [T3 (triiodothyronine), T4 (thyroxine), TSH (thyroid-stimulating hormone)], tolerability (via questionnaire), vital signs, and dietary intake. Results: Statistical analyses displayed ten significant main effects (p < 0.05) with white blood cells, lymphocytes, neutrophils, urinary pH, thyroxine, urination frequency, calcium, calories, fat, and cholesterol. Interactions for time and group (p < 0.05) were observed for MCV, eGFR, potassium, overall tolerability, bloating, and cramping—demonstrating mild GA disturbances. Little to no change of physiological relevance was noted for any outcome variable, regardless of dosing level. Conclusions: Our results indicate the product was well-tolerated at all dosing levels and no significant adverse changes occurred in any of the test parameters compared to the placebo group, indicating relative safety of ingestion over a 4-week treatment period, at the volumes used, and outside the context of physical stress.

## Linked entities

- **Chemicals:** L-alanine (PubChem CID 602), L-glutamine (PubChem CID 5961), niacin (PubChem CID 938), pantothenic acid (PubChem CID 988), pyridoxine (PubChem CID 1054), cobalamin (PubChem CID 73415824), ascorbic acid (PubChem CID 9888239)

## Full-text entities

- **Diseases:** GA disturbances (MESH:C536833), cramping (MESH:D009120), dehydration (MESH:D003681), bloating (MESH:C535647)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11174401/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11174401/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC11174401/full.md

---
Source: https://tomesphere.com/paper/PMC11174401